Lumos’ FebriDx test has been identified as a useful tool in the fight to ‘outsmart’ antimicrobial resistance in an article titled
“Not 'if' but 'when': Antibiotic resistance poses existential threat for modern medicine” published in USA Today.
The growing challenge of antibiotic resistance is making headlines, as the US grapples with the looming costs of antimicrobial resistance to the healthcare sector. With deaths of over 5 million each year, experts predict that this figure will grow into the tens of millions within a few decades, if not tackled with a sense of urgency.
An excerpt:
“On the horizon are tests that help doctors quickly distinguish between an infection caused by a virus, which won't benefit from an antibiotic, and one caused by bacteria, which might. Earlier this month, the Food and Drug Administration cleared a test from Lumos Diagnostics of Australia that can rapidly identify a bacterial infection.”
Antibiotics remain a powerful and targeted tool in preserving human health, and the urgency of addressing AMR must be balanced with the need for precision in medical care.
Click here to read the article